A randomized, controlled trial of aspirin in persons recovered from myocardial infarction.
A randomized, controlled trial of aspirin in persons recovered from myocardial infarction.
复制标题
一项针对心肌梗塞康复者的阿司匹林随机对照试验。
DOI：
10.1001/jama.1980.03300330019023
复制
发表时间：
1980
期刊：
影响因子：
--
通讯作者：
T. Bjornsson
中科院分区：
文献类型：
--
作者：
K. Wolfram;T. Bjornsson
阿司匹林心肌梗塞研究 (AMIS) 是一项由国家心肺和血液研究所资助的多中心、随机、双盲和安慰剂对照试验，旨在测试至少经历过一次心肌梗塞 (MI) 的男性和女性定期服用阿司匹林是否会导致三年内总死亡率显着降低。还评估了特定原因的死亡率、非致命事件和副作用。在 13 个月的时间里，4,524 名年龄在 30 岁至 69 岁之间的人被随机分配每天服用 1 克阿司匹林（2,267 人）或安慰剂（2,257 人）。各种措施表明患者对研究方案的高度依从性。阿司匹林组在整个随访期间的总死亡率为 10.8%，安慰剂组为 9.7%。阿司匹林组的三年总死亡率为 9.6%，安慰剂组为 8.8%。安慰剂组中确定的非致命性心肌梗死的百分比为 8.1%，阿司匹林组中为 6.3%。阿司匹林组的冠心病发病率（冠心病死亡率或明确的非致命性心肌梗死）为 14.1%，安慰剂组为 14.8%。阿司匹林组有 23.7% 的人出现消化性溃疡、胃炎或胃粘膜糜烂的症状，安慰剂组有 14.9% 的人出现消化性溃疡、胃炎或胃粘膜糜烂的症状。根据 AMIS 结果，不建议 MI 幸存者常规使用阿司匹林。
The Aspirin Myocardial Infarction Study (AMIS) was a National Heart, Lung and Blood Institute-sponsored, multicenter, randomized, double-blind, and placebo-controlled trial designed to test whether the regular administration of aspirin to men and women who had experienced at least one documented myocardial infarction (MI) would result in a significant reduction in total mortality over a three-year period. Cause-specific mortality, nonfatal events, and side effects were also evaluated. Over a 13-month period, 4,524 persons between the ages of 30 and 69 years were randomized to either 1 g of aspirin per day (2,267 persons) or placebo (2,257 persons). High levels of patient compliance to study protocol were indicated by various measures. Total mortality during the entire follow-up period was 10.8% in the aspirin group and 9.7% in the placebo group. Three-year total mortality was 9.6% in the aspirin group and 8.8% in the placebo group. The percentage of definite nonfatal MI was 8.1% in the placebo group and 6.3% in the aspirin group. Coronary incidence (coronary heart disease mortality or definite nonfatal MI) was 14.1% in the aspirin group and 14.8% in the placebo group. Symptoms suggestive of peptic ulcer, gastritis, or erosion of gastric mucosa occurred in 23.7% of the aspirin group and 14.9% in the placebo group. Based on AMIS results, aspirin is not recommended for routine use in patients who have survived an MI.